<SEC-DOCUMENT>0001144204-15-016109.txt : 20150316
<SEC-HEADER>0001144204-15-016109.hdr.sgml : 20150316
<ACCEPTANCE-DATETIME>20150316091349
ACCESSION NUMBER:		0001144204-15-016109
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150316
FILED AS OF DATE:		20150316
DATE AS OF CHANGE:		20150316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		15701309

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v404568_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of March, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>XTL Biopharmaceuticals Ltd.&#9;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>85 Medinat Hayehudim St., Herzliya </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pituach, PO Box 4033,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Herzliya 4614001, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 65%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>(Address of principal executive
offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: center; font-size: 10pt; text-indent: 0">Form 20-F <FONT STYLE="font-family: Wingdings">&#120;</FONT></td>
    <TD STYLE="width: 50%; padding: 0; text-align: center; font-size: 10pt; text-indent: 0">Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT></td>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt">No <FONT STYLE="font-family: Wingdings">&#120;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &ldquo;Yes&rdquo; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated March 16, 2015 is hereby incorporated by reference into the registration statements on
Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 53px; width: 176px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annual Letter to Shareholders of XTL
Biopharmaceuticals Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 16, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Shareholders, Associates, and Friends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we begin the new year, I would like
to take this opportunity to reflect on our progress in 2014 while also looking forward to continued success in 2015. I am very
proud of our accomplishments throughout the year. We built a strong management team and strengthened our Board of Directors with
the addition of four new members who have a wealth of knowledge in drug development and the capital markets that will help guide
the Company forward. We remain focused on creating value for our shareholders with the development of our assets for Lupus and
Multiple Myeloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management and Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the start of 2014, the Company completed
the transition to a new management team led by myself as Chief Executive Officer and David Kestenbaum as Chief Financial Officer.
I was formerly the CEO of Proteologics Ltd. and a Senior Director at Teva Pharmaceuticals (&ldquo;Teva&rdquo;) and David was formerly
the CFO of Colbar LifeScience, a division of Johnson &amp; Johnson, and Unilever in Israel. During the year, we added four new
directors with extensive drug development and capital markets experience to the Board. Dr. Jonathan Schapiro of Stanford University
and Sheba Medical Center in Israel and Dr. Dobroslav Melamed, recently of SciVac/SciGen, both bring extensive drug development
experience. Mr. Doron Turgeman and Mr. Shlomo Shalev both have strong financial backgrounds. I look forward to their contributions
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisition and Development of hCDR1
for the Treatment of SLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In early 2014, we in-licensed hCDR1, a
Phase II-ready asset for the treatment of SLE (lupus). Lupus is a debilitating autoimmune disease and represents a large unmet
medical need, with only one new treatment approved by the FDA in the past 50 years. A fourth quarter announcement by Eli Lilly
that it discontinued development of a Phase III asset in this space further emphasized the unmet need and highlighted the significant
opportunities for our hCDR1 asset and positions the Company to garner significant interest from clinicians, lupus patients and
partners and will no doubt lead to &ldquo;game changing&rdquo; opportunities for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">hCDR1 is a peptide that has a unique mechanism
of action and has been published in more than 40 peer-reviewed papers. The drug has been administered to over 400 patients in two
Phase I trials and a Phase II (PRELUDE) trial. The trials demonstrated that hCDR1 is well tolerated by patients and has a favorable
safety profile. Although the Phase II trial did not achieve its primary efficacy endpoint, hCDR1 displayed encouraging results
in its secondary clinical endpoint, the BILAG index. Following the Phase II PRELUDE trial, the FDA issued new guidelines and now
recommends the BILAG index as a primary endpoint in future lupus trials. Given the FDA&rsquo;s recommendation and the positive
findings with respect to the BILAG index, the Company is planning to discuss the results with the FDA and has been preparing for
the initiation of a new clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has taken a number of steps
to move the program forward:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We established a world-class Clinical
Advisory Board to include Dr. Daniel Wallace of Cedars-Sinai Medical Center, a former President of the Lupus Foundation of America
and operator of the largest lupus clinic in the US, Dr. Murray Urowitz of the University of Toronto and Toronto Western Hospital,
who established the University of Toronto Lupus Clinic and the Lupus Databank Research Program and Dr. David Isenberg of University
College London Hospitals who is, among other things, the author of the BILAG index.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We reached an agreement to transfer the
Investigational New Drug application that was in place for the PRELUDE study to XTL.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We prepared a draft protocol for the planned
trial with key opinion leaders.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We completed production of the peptide
by Polypeptide, a CMO based in California.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We continue discussions with the FDA to
explore our options in order to expedite the regulatory pathway.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Finally, we have held preliminary discussions
with a number of potential partners/licensees as part of our partnering program.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Development of rHuEPO for the Treatment
of Multiple Myeloma </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also during 2014, the Company initiated
discussions with the FDA regarding the design of a Phase II clinical trial for rHuEPO for the treatment of multiple myeloma. The
company owns a use patent and has obtained orphan drug designation for this application of the drug. The Phase II study is designed
to demonstrate a significant survival benefit from the treatment of end-stage multiple myeloma patients with rHuEPO in a clinical
setting. A dramatic survival benefit was demonstrated in a number of patients and results have been published in medical journals.
The Company is concluding discussions with a leading pharmaceutical company for the supply of rHuEPO in the planned trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholders and Fundraising</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company filed a shelf registration
statement with the United States Securities and Exchange Commission that became effective in April to raise the funds necessary
to fund the next stage of development for our rHuEPO and hCDR1 assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter, Mr. Alex Rabinovich,
our largest shareholder, increased his stake in XTL to 18.8% of issued and outstanding shares. He also announced an investment
in InterCure, an XTL subsidiary, which effectively affords him control over an additional 2% of XTL shares held by InterCure. Mr.
Rabinovich, an Israeli biotech investor, brings a wealth of knowledge and experience in the biotech industry. We appreciate his
confidence in the management team and the direction we have taken the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we look ahead to 2015, we have a number
of exciting opportunities that <FONT STYLE="font: 10pt Times New Roman, Times, Serif">we believe will add value to the Company
</FONT>and, ultimately, to our shareholders. We plan to leverage these opportunities to raise the capital necessary to develop
our clinical assets and strategically position the Company to partner, license or further develop these assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>New Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Spurred on by the developments of 2014,
I would like to share a few highlights with you about our strategy for 2015. We will share the details of this strategy with you
in a separate communication in the near future:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Focus on our two main assets: hCDR1 for
the treatment of SLE and rHuEPO for the treatment of multiple myeloma. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain widespread awareness of the positive
safety and efficacy data related to hCDR1 with the publication of the PRELUDE trial results.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Engage with the FDA to expedite the development
of hCDR1 including new approaches to regulatory issues.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Take advantage of the renewed interest
in potential therapies for lupus by identifying partnering opportunities for the development of hCDR1. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiate a Phase II clinical study of
rHuEPO for the treatment of multiple myeloma.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are on the threshold of what we expect
to be a very exciting year. We look forward to working with you, our team and our partners to leverage our assets and create value
for our shareholders. We will continue to share news of our progress throughout the coming year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Josh Levine, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About XTL Biopharmaceuticals Ltd. (&quot;XTL&quot;)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL Biopharmaceuticals Ltd., a biopharmaceutical
company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical
needs. XTL is focused on late stage clinical development of drugs for the treatment of lupus, multiple myeloma and schizophrenia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL is a public company traded on the Nasdaq
Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv
Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations, XTL Biopharmaceuticals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: ir@xtlbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">www.xtlbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements included in this
press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim
the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td>
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; text-indent: 0"><b>XTL BIOPHARMACEUTICALS LTD.</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 60%">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 5%">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 35%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Date: March 16, 2015</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">By:</td>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; text-indent: 0">/s/ Josh Levine</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Josh Levine</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Chief Executive Officer</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"``U`+`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UMKZTC8J]
MS"K+P5+@$?K6;XAUD67AV\NK&5))HTP"I!VDD#/X9S^%<Q\1?#>Z(:M:(`R\
M7"J,9!Z-]>Q_#TKC_#NJ)IFI@W(\RTG4Q7"-R"C=?RZ_A7I4,'&=/VL7>W3T
MZ'G5L5*$W3:M?J55U:^2]^UK=S"XSGS-YR?QKVC2=62ZT:SN;R6*&6:$.RLP
M7)QR0#VKF3\/-%MV-[)=3&T4&4J6&W;C/7TQ^-<'KNJG5M4DG5=D*@1PQC@(
M@X`_SZUU3C3QK2AI;=V_`YX2GA$W+6_3]3V^.]MIFVQW$3,>RN":;_:5G_S]
M0?\`?Q?\:Y'P'X;-CI;:A<J?M-RO[L$<HG;\3U^F*\^.B:KD_P#$NO?^_+?X
M5Q4\'3G.4>?1?B=4\54A%2<=SW#^T;/_`)^H/^_J_P"-)_:-G_S]0?\`?U?\
M:\*N-/O;-`]U:W$*L=H:2-E!/IR*B@AGNI1%;QR2R'HJ*6)_`5TK*X-7Y]/0
MQ_M&2=N4]Z_M*S_Y^X/^_B_XT?VE9_\`/U!_W\7_`!KP_P#L35?^@=>_]^6_
MPJI(DD,C1RJR.IPRL""#Z$&B.60EM/\``3S":WB?0,4L<R;HG5U]5((I_>N7
M^'/_`"*4/_71_P#T*NIKRJL.2;CV/2I3YX*7<0X`YX`J&*YAF)$<J.1SA6!-
M+=?\>LO^X?Y5Y_\`#_)UJ;G/[D_^A+5TZ7/"4K[&%;$.G5A3M>YZ/1245B=8
MUV5%+.0%')).,5'%/%,#Y4B/CKM(.*K:S:R7VD7-M#CS)4*KG@9K&\):!>:*
MUT;PQGS0H78Q;IG/;WK2,(N#DWJNASSJ35504;I[OL=3124M9G0%%%%`$,T2
M3PO%*H9'!5@1P0>"*\3\3Z&^@:Q);8/DM\\+'NI_J.AKW#/2N-^)*V3:`C7)
MQ<+)^XQU)[CZ8Z^^*[LOKNG54>C_`*N<6-I*=-RZHXB?Q7<S>%8M&.1L?#29
MZQCE5_/]`*F\$^'#KFJB69<VEN0TF>C'LOX]_;ZUS5>Q^!)+)_"\`L>-I(F!
MZ[^^?TQ[8KT\9+ZM2?LU:[_IGGX:/MZJYWLCI0```!C%+@4M%?/'NG#_`!2_
MY`5K_P!?`_\`06KE/AY_R-]M_N/_`.@FNK^*7_("M?\`KX'_`*"U<I\//^1P
MMO\`<?\`]!->UA_]RE\SQZ_^]Q]4>Q8KPWQ5_P`C3J7_`%W;^=>Y5X;XJ_Y&
MC4O^N[?SK'*OXC]#;,O@7J>D?#G_`)%&'_KJ_P#Z%755ROPY_P"11A_ZZO\`
MSKJJXL3_`!I>K.O#?PH^A#=?\>LO^X?Y5YAX7U>'1KNXN9P3^Z*JHZL<CCVK
MT^Z_X]I?]P_RKR[PKIJZEKL4<HW1H#(P/<#H/SQ6^%Y?9SYMCS\PYO;4^3?6
MQK-K/BF_7S[>&2.'J`D0P1[9!)J?2_&]Q#=_9M9C`&=IDV[2I_VA_P#JKN,8
M&!7&_$#3T-K#?*N)$;RV('4$<9^A'ZTJ=2G4ER2BDGV'6HUL/'VL9MM;I[,Z
M35;UK/2+B[@VLT<9=<\@_E65X3\0W6N-="ZCB01!2OE@C.<YSDGTK/L+U[OX
M>7*N<F&-H\^H&"/T./PJ'X<L`=0)Z`(3_P"/4O8Q5*=UJF5]9E.O3L[)J[1O
MZ_XFMM#C",/,N6&5C!QQZD]A7-1Z[XIU-?.LX2L?.#'$,'Z%LYJCI\7_``DW
MBUGN`3&[&1E)_A'1?Y"O2U544*JA5`Q@<8HER8=)<J;>]R:;J8QRDI-13LK=
M3B;/QK>65W]GUNW('=@FUE]R.X_*NUAF2XA26)@T;J&5AW!&0:P?&.EQWVC2
M3[0)K<%U8#G'\0^F.?PJMX!OFN-)EMG.3;O\N>RGD#\P:FI&$Z?M(JS6Z-:,
MZE*O["H[IJZ?4Z>69((FEE8*B`LS$X``ZFO%?%.OOX@UAYP2+=/DA4]AZ_4]
M?_U5U7Q%\2@)_9%HX)/-PP/3!X7^I_#WKF/".@G7=:CB<?Z-%AYC_L]E_$\?
MGZ5W8*C&C3=>I\C+%U75FJ,!T_A2[@\*Q:NV?F;+1XY6,\*WXG]"*7P=XB;0
M-74RL?LD^%E'IZ-^'\LU[%-:Q3VCVTB*T+J49,<;2,8KP_7]'DT+6)K.3)53
MF-C_`!*>A_SW!K7#8A8M2IU/Z7_`(KT'AG&I#^F>Z*RN@92"#R"#UI]<+\.O
M$?VNU_LJY?,T*YB8G[R>GU'\OI7=5XU:DZ4W!]#U*-558*2.(^*7_(!M?^O@
M?^@M7*?#S_D<+;_<?_T$UU?Q2_Y`5K_U\#_T%JY3X>?\CA;?[C_^@FO6P_\`
MN4OF>;7_`-[CZH]BKPWQ5_R-&I?]=V_G7N5>&^*O^1HU+_KNW\ZPRK^(_0US
M+X%ZGI'PY_Y%&'_KJ_\`Z%755X=IWBO5M)M%M;&Z\J!26"^6C<GKR035K_A/
M?$/_`#__`/D)/_B:NMEU6=1R35F_ZZ$TL=3A!1:>B/8;K_CUE_W#_*O/OA^P
M&MR@G!:$X'KR*Y__`(3KQ`X*M?Y5N"/*3I_WS4^D2W=G<F^LHRQML%QVVG@Y
M]J(X.=*G*,FM3EQ&+C*M3FD]-SU_KUKFO'<H3PZ4)YDD4`?3G^E,A\=Z9)`&
MF$L<F.4VYY]C_P#JKF]7U.Y\6ZG%;V4+>2IQ&IZ\]68]OZ5R4*$XU%*2LEJ=
M>+QE.=)QIN[>EEYFCHL13X?:BY!`<NPSW``']*;X`C\V+5$'!:-`/QW5OZC9
M)IW@NXM4.1%;E2?4]S^>:Q/AQ][4/I'_`.S5JY\U*<EW_P`CG5+DQ%*#Z)F;
MX'81>)-CG#-$R`'N>#C]#7I6:\]\2Z5=:)K/]J60;RF?S`P&=C'J#['^N*V;
M+QWITL`-V)()0.0%+`GV(_K4XB#K6J05TT7@JT<-S4:KLT]+]4;&ONL.@7S.
M<#R&4?4C`_4US?PYC81W\A'R,8U!]QNS_,5G^(O$DFOLEAIL<GE,1GCYI#V&
M!V_SVKL?#FE_V3HT,!XE8;Y?]X]1^'`_"HE%TJ#C+=O8TA-8C%*<-HK?O<:_
MA;1I9&=].@9V))8KDDGJ:MV6F66EJZV-M'`'.6"#&3117)[6<E9MGI1I03ND
M7:H7VBZ?J;JU[:Q3,HP"ZYP***:DXNZ&XJ2U(;?PWI-I<)-;V$$<L?*LJX(K
M5[4442DY/5BC%16B*E_IMIJ<2QWL"3(K;@KC(!QC^M5[3P_IEC<">ULH8I5S
MAT7!&1S111&<N2UR7"/->QI]:R9_#6D7-P\TUA`\KL2S%>23WHHIQDXO1E.*
MDM4,_P"$4T/_`*!EO_WS1_PBFA_]`RW_`.^:**KV]3^9_>+V-/\`E0H\)Z'G
M(TRW_P"^:MV^E65D6-M:PQ%A@E%`R***S=6<MY,%2II_"BG<>%='NY=\ED@8
M_P!QF4?D"*O6FGVUA$$M((XE]%7&?K113G4E:UQ1HTXRNHHFN(8[B%HID#QN
M,,IZ&J]EIMIIY<VL"1;\;M@QG'2BBB+=K#E%.29;=0RD,`0>H-8\_A71[J3=
M)8H&_P!AF0?DI`HHIQDX[,<J4*B]])EVQTJST]<6EO''GN!R?J>IJ[112;;>
(H1BHJT4?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
